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We reported that immunization with recombinant proteins derived from vaccinia virus (VV) particles could provide protection against
infection. Here we describe the physical and antigenic properties of the L1R membrane protein. The recombinant protein (L1R(185t)) was
secreted as a monomer and correct folding was suggested by the presence of three intramolecular disulfide bonds and binding to
conformation-specific monoclonal antibodies (MAbs). Furthermore, anti-L1R(185t) rabbit antisera exhibited potent virus-neutralizing
activity against the IMV form of VV. We raised six MAbs against L1R(185t). Three recognized linear epitopes (residues 118–128) and
neutralized IMV infectivity. These MAbs blocked binding of each other to L1R(185t) but failed to block binding of two previously described
neutralizing anti-L1R MAbs, 7D11 and 2D5. The latter two antibodies blocked each other in binding L1R(185t). Thus, two antigenic sites on
L1R overlap functional domains and based on recent structural studies these are found in accessible regions of the IMV L1R protein.
D 2005 Elsevier Inc. All rights reserved.Keywords: Vaccinia virus; L1R; Disulfide; Neutralizing; Monoclonal; Epitope; 2D5; 7D11; Baculovirus; AntibodyIntroduction
Vaccinia virus (VV) is the prototypical member of the
Orthopoxvirus genus that also includes cowpox, monkey-
pox, ectromelia and variola (Moss, 2001). Although VV has
no known natural host, its use as a vaccine against variola
(the causative agent of smallpox) led to the eradication of
smallpox as a human disease. VV replicates in the
cytoplasm of the infected cell and produces two infectious
forms: intracellular mature virus (IMV) and extracellular
enveloped virus (EEV). IMV consists of a DNA-containing0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.07.006
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of Cancer Research, London, SW3 6JB, UK.protein core surrounded by a lipid membrane and several
IMV-specific proteins. These particles are assembled in the
cytoplasm and are subsequently wrapped with additional
membranes derived from modified trans-Golgi or endo-
somal cisternae before exocytosis. The extracellular doubly
wrapped particles known as EEV contain an additional set
of viral glycoproteins, and as a result different antibodies are
needed for neutralizing this form. The extracellular virions
are important for virus dissemination both in vitro and in
vivo (Boulter and Appleyard, 1973; Payne, 1980) In
contrast to EEV, IMV accumulate within infected cells and
are only released as a result of cell lysis (Smith et al., 2002).
L1R is synthesized late in infection and is a myristylated
component of the IMV membrane (Franke et al., 1989,
1990; Ravanello and Hruby, 1994a; Wolffe et al., 1995).
Blocking of L1R expression aborts morphogenesis and005) 59 – 71
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Hruby, 1994b). Importantly, L1R is a major target of VV
neutralizing antibodies (Ichihashi and Oie, 1996; Wolffe et
al., 1995), suggesting a role in virus entry. Mice vaccinated
with a plasmid encoding L1R produce IMV-neutralizing
antibodies although the animals are not protected from a
lethal virus challenge. However, mice immunized with
DNA expressing both L1R and EEV proteins are protected
from such a challenge (Hooper et al., 2000, 2003).
In the first part of our study we produced a purified
soluble truncated form of L1R and characterized its
properties. Mice vaccinated with this baculovirus-produced
L1R are immune to a 5 LD50 VV WR challenge (Fogg et al.,
2004). When the challenge virus dose was increased 20-
fold, mice immunized with a combination of IMV and EEV
proteins survived while those immunized only with
L1R(185t) or B5R(275t) succumbed. This demonstrates
the superiority of protein combinations as a vaccine
candidate. Since L1R(185t) protects mice in a lethal dose
challenge and it could become a component of a candidate
subunit vaccine, we aimed to characterize it better. We
showed that L1R(185t) is a monomer by sedimentation
studies and we elucidated its disulfide bond pattern by mass
spectroscopy. These bonds connect amino acids (aa) 34–57,
49–136 and 116–158 and mirror those seen in a crystal
structure of L1R that had been produced in bacteria (Su et
al., 2005). Secondly, we produced six anti-L1R monoclonal
antibodies, four of which neutralized IMV infectivity and
formed one group that recognizes a linear epitope between
residues 118 and 128. The other two MAbs had no effect on
IMV infectivity and blocked binding of each other to
L1R(185t), suggesting that both recognize the same anti-
genic site. Both the peptide mapping and biosensor blocking
studies suggest that the neutralizing antibodies presented
here bind to a different neutralizing epitope than the epitope
recognized by the only two previously reported neutralizing
antibodies 2D5 and 7D11 (Ichihashi and Oie, 1996;
Ichihashi et al., 1994; Wolffe et al., 1995). Thus, our data
suggest that two of the three antigenic sites on L1R overlap
functional domains.Fig. 1. Recombinant vaccinia virus L1R protein produced in baculovirus.
(A) L1R is depicted as a stick diagram. Below it is a diagram of the
recombinant protein. Putative transmembrane domain (TMD) is a grey
rectangle. Black lollipops represent sites for N-glycosylation, M represents
the myristoylation site on Gly2, C’s represent cysteines and H6 represents
the 6 Histidine tail. Additional amino acid residues appended to the
recombinant protein as a result of cloning into the pVT-Bac vector are also
shown. (B) L1R(185t) was purified by nickel–NTA affinity chromato-
graphy, separated by SDS–PAGE (10–20% Tris–glycine gel) under
reducing conditions and stained with silver nitrate. (C) L1R(185t) was
separated by SDS–PAGE (10–20% Tris–glycine gel) under reducing (lane
1) or nonreducing (lane 2) conditions and transferred to nitrocellulose. The
blot was probed with a monoclonal antibody directed against the His-tag.
The bands were revealed by autoradiography following addition of a
chemiluminescent reagent. The positions of molecular weight markers are
shown in kilodaltons.Results
Expression of a secreted form of the L1R protein in insect
cells
During a VV infection, L1R is synthesized and incorpo-
rated into the IMV membrane instead of transiting the
secretory pathway. Because of the unusual manner by which
L1R is synthesized in VV-infected cells, the choice of which
portion of L1R to express in baculovirus to obtain a
correctly folded and soluble form of the protein was not
obvious. We could express either the N- or the C-terminal
domains as soluble forms since it was unclear which
terminus was oriented towards the cytoplasm. The predictedtransmembrane domain (TMD) of L1R encompasses resi-
dues 186–204 but there is no predicted N-terminal signal
sequence present. L1R produced in VV-infected cells is
myristylated at its N-terminus (Franke et al., 1989, 1990),
suggesting that this part of the protein may associate with
membranes and orient much of the protein (aa 1–185)
towards the cytoplasm. Remarkably, L1R has stable
disulfide bonds in its cytoplasmic domain (Locker and
Griffiths, 1999). Instead of using known cellular pathways
for disulfide bond formation in the relatively oxidizing
endoplasmic reticulum (ER) (Frand et al., 2000; Tu et al.,
2000), VV has genes for three cytoplasmic thiol oxidor-
eductases and these enzymes comprise a complete pathway
for cytoplasmic disulfide bonding of IMV membrane
proteins, including L1R (Senkevich et al., 2002). These
oxidoreductases would allow the formation of disulfide
bonds on the N-terminus of L1R.
In order to express L1R in the baculovirus system, we
decided to clone residues 1–185 of L1R adjacent to
sequences for the melittin signal peptide. The objective
was to create a recombinant baculovirus that upon infection
of insect cells would express L1R as a secreted protein in
which the correct disulfide-bonded pairs would form in the
ER instead of the cytoplasm (Fig. 1A). In addition,
Fig. 2. Antigenic characterization of L1R(185t). (A) VIG reacts with
L1R(185t). An ELISA plate was coated with purified L1R(185t) (closed
circles) and incubated with dilutions of VIG. Bound IgG was detected using
peroxidase-conjugated anti-human secondary antibody followed by ABTS
substrate. Also shown as a reference is VIG reactivity against B5R(275t) as
a positive control and against Nectin-1(346t) as a negative control (Aldaz-
Carroll et al., 2005; Krummenacher et al., 1998). (B) Western blot of a
detergent extract of VV proteins present in VV-infected cells. Samples were
subjected to SDS–PAGE under reducing and denaturing conditions,
electrophoresed in a 10–20% Tris–glycine gel, transferred to nitrocellulose
and probed with an anti-L1R(185t) rabbit polyclonal IgG (R180). Lane 1:
extract from mock-infected BSC-1 cells; lane 2: extract from VV-infected
cells. Molecular weight markers are shown in kilodaltons. (C) Vaccinia
virus (IMV) was neutralized by rabbit polyclonal IgG (R180). BSC-1 cell
monolayers were infected with IMV previously incubated with R180 for 1
h at 37 -C. After 18 h at 37 -C, cells were fixed and stained with crystal
violet. Data are expressed as the number of plaques/well. Each value
represents the average plaque number of duplicate measurements from one
experiment. R178 (a rabbit polyclonal against VV EEV glycoprotein
A33R) and R176 (a rabbit polyclonal against HSV glycoprotein gH/gL)
were included as negative controls.
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myristylaton. L1R(185t) was purified from the culture
supernatant by nickel–chelate affinity chromatography.
The protein was analyzed under reducing and denaturing
conditions of SDS–PAGE followed by silver staining (Fig.
1B) or Western blotting (Fig. 1C, lane 1). L1R(185t)
resolved as several closely migrating bands of 19–25 kDa
that likely represent differing levels of N-glycosylation of
the three predicted sites (Fig 1A) (see below). Under
nonreducing conditions of electrophoresis, L1R(185t)
migrated more rapidly in the gel suggesting a more compact
structure (Fig. 1C, lane 2). A similar mobility difference was
observed for L1R from VV-infected cells (Wolffe et al.,
1995). It was suggested that intramolecular disulfide bonds
maintain the protein in a more compact shape (Wolffe et al.,
1995). Our data suggest that L1R(185t) also contains
intramolecular disulfide bonds (see below).
L1R(185t) resembles the natural form of L1R in antigenic
properties
The presumptive formation of disulfide bonds and
secretion of L1R(185t) suggested that it was correctly
folded. To assess the antigenic properties of L1R(185t), we
determined its reactivity with human vaccinia immune
globulin (VIG). ELISA plates were coated with either
purified L1R(185t), B5R(275t) as a positive control (Aldaz-
Carroll et al., 2005; Bell et al., 2004) or the herpesvirus
receptor protein nectin-1(346t) (Krummenacher et al., 1998)
as a negative control and each was incubated with human
VIG (Fig. 2A). VIG recognized both B5R(275t) and
L1R(185t) but not nectin-1. The ability of L1R(185t) to
react with VIG indicated that it contained some of the
antigenic epitopes found in the corresponding virion protein
from vaccinated humans.
Antibodies against B5R are mainly responsible for the
ability of VIG to neutralize EEV (Bell et al., 2004). To
estimate how much of the IMV neutralizing capacity of VIG
was due to the presence of neutralizing anti-L1R antibodies,
we added increasing concentrations of L1R(185t) to VIG and
looked for a reduction in IMV neutralization by VIG. As a
control, 10 Ag of L1R(185t) blocked 100% of the neutralizing
activity of VMC-2 (a neutralizing anti-L1R antibody
described below). Surprisingly, neither 10 Ag nor 50 Ag of
L1R(185t) blocked the neutralizing activity of VIG (0%
reduction, data not shown).We conclude that most of the anti-
IMV neutralizing activity of VIG is not due to L1R and likely
involves another protein(s).
In a second experiment we generated two polyclonal
antibodies against L1R(185t) (R179 and R180). A
detergent extract of VV-infected cells was subjected to
SDS–PAGE and a Western blot was probed with R180.
This antibody reacted with a band of the expected size for
VV L1R (lane 2, Fig. 2B). We next used a plaque
reduction assay to test whether R180 neutralized IMV
infectivity. As controls, we also tested R178 (raisedagainst A33Rt, a recombinant VV EEV glycoprotein)
and R176 (raised against herpesvirus glycoproteins gH/
gL). R180 neutralized IMV infectivity such that 10 Ag/ml
reduced the starting titer by 50% (Fig. 2C). These data are
further evidence of the antigenic resemblance between
L1R(185t) and VV L1R and affirm that we were correct
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secreted protein.
L1R(185t) is a glycosylated monomer with three disulfide
bondsFig. 3. Structural analysis of L1R(185t). (A) C(s) vs. sedimentation
coefficient distribution calculated from the boundary velocity data of
L1R(185t) (not shown). The differential distribution c(s) is in units of
absorbance per Svedberg. Inset: Molar mass distribution c(M) calculated
from the c(s) distribution and the weight average fitted frictional ratio f/f0 of
1.287. The differential distribution c(M) is in units of absorbance per molar
mass multiplied by 100,000. (B) Deglycosylation of L1R(185t). L1R(185t)
was denatured and reduced, then treated with PNGase F to remove N-linked
glycans. (C) Alkylation of L1R(185t). Purified L1R(185t) was treated with
the alkylating reagents NEM (N-ethylmalemide) or AMS (4-acetamido-4V-
malemideylstilbene-2,2V-disulfonic acid) after no reduction or after reduc-
tion with TCEP (Tris(2-carboxyethyl)phosphine hydrochloride). Molecular
weight markers are shown in kilodaltons. Samples in panels B and C were
analyzed by SDS–PAGE and Western blotting with anti-tetra His.(i) Sedimentation data. We performed sedimentation
studies to determine the oligomeric state of
L1R(185t). The predicted mass of monomeric
L1R(185t) is 20,755 on the basis of amino acid
composition. According to sedimentation velocity the
molar mass of L1R(185t) was 20,588 (Fig. 3A). By
sedimentation equilibrium the molar mass was about
10% lower at 18,690 (data not shown). The combined
data unequivocally established that L1R(185t) is a
monomer under the experimental conditions used.
(ii) Glycosylation. Virion-associated L1R is not nor-
mally glycosylated because the protein is located in
the cytoplasm rather than the ER lumen. However,
the recombinant L1R(185t) should be glycosylated
at one or more of the predicted sites (Fig. 1A)
since it traveled through the secretory pathway of
the infected cells. Treatment of L1R(185t) with
PNGase F increased its electrophoretic mobility,
indicating that N-linked oligosaccharides were
present on L1R(185t) and were removed by the
enzyme treatment (Fig. 3B, compare lane 1 with
lane 2). Thus, L1R(185t) differs from L1R pro-
duced by VV-infected cells in terms of glycosyla-
tion. The presence of carbohydrates on L1R(185t)
was confirmed using different digoxigenin-labeled
lectins. This procedure identified the presence of
terminal mannose moieties associated with high-
mannose N-glycan chains, but no O-linked glycans
were detected (data not shown).
(iii) Intramolecular disulfide bonds. Proper formation of
IMVs depends on disulfide bond formation carried
out by a unique set of vaccinia-expressed thiol
oxidoreductases (Senkevich et al., 2002). The six
cysteine residues of viral L1R are disulfide bonded
by this mechanism, and it was important to
determine if the baculovirus-expressed L1R(185t)
also contained intramolecular disulfide bonds. To
determine the state of thiols in L1R(185t), we treated
the protein with the alkylating agents N-ethylmale-
mide (NEM) or 4-acetamido-4V-malemideylstilbene-
2,2V-disulfonic acid (AMS) before or after reduction
with Tris(2-carboxyethyl)phosphine hydrochloride
(TCEP). Treatment of nonreduced L1R(185t) with
either NEM or AMS had no effect on its electro-
phoretic mobility, indicating the absence of free
thiols (Fig. 3C, compare lanes 2 and 3 with the
control in lane 1). Reduction of L1R(185t) coupled
with alkylation by NEM resulted in a mobility shift
consistent with the additional mass of NEM (Fig.
3C, lane 4). A greater mobility shift (approximately3.0 kDa) was seen when reduced L1R(185t) was
treated with AMS, since each free thiol bound by
AMS contributed 0.5 kDa to the mass of the protein
(Fig. 3C, lane 5). This indicates that all six cysteines
are in disulfide bonds and thus L1R(185t) was
efficiently disulfide bonded while transiting the
secretory pathway.
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lation site by mass spectroscopy. To assign the
disulfide bonds to specific cysteine pairs, L1R(185t)
was treated with trypsin and the peptides were
analyzed by mass spectroscopy. We anticipated that
tryptic peptides containing free cysteines would be
missing in the digest, and that larger ones that were
disulfide linked would be present. Indeed the missing
peptide areas were between aa 34–84 and 114–161
(see Table 1). These peptides contained cysteines,
except for a two aa segment (126–127). A peak
measuring 4439.0, calculated as 4439.0, matched the
expected mass of disulfide-linked peptides between aa
34–44 and 55–84. The fragment spectra of this ion
showed overlapping C-terminal sequences SAATE-
TYSGLTPEQK and IEIGNFYIR (see ahead Fig. 6A),
which verified the peptide assignments. Thus, the first
disulfide was established between Cys34 and Cys57.
The next two peptide peaks (measuring 4318.1,
calculated as 4318.1, and measuring 4077.0, calcu-
lated as 4077.0, respectively) corresponded to disul-
fide linked peptides aa 45–54 and 126–155 and to
peptides aa 45–54 and 128–155 (missing the two
segment aa mentioned above). Both peaks correspond
to peptides that connected via cysteines 49 and 136.
When the MS/MS fragment spectrum of the later
disulfide-bonded peptide was examined, the C-termi-
nal sequence from aa 145–155 (NLEFINTGSSK)
was manually identified. Thus, the second disulfide
was established between Cys49 and Cys136. A fourth
peak (measuring 1866.9, calculated as 1866.9) corre-
sponded to peptide aa 114–125 linked to 156–161.
The C-terminal sequence of this disulfide peptide pair
was SSAVVDNK which confirmed the identification.
Thus, the third disulfide was between Cys116 and
Cys158. We also examined the peptide digest after
reduction with TCEP by mass spectroscopy. The
peaks assigned to the disulfides were not observed,
and a Mascot search of the data showed 100% protein
coverage in the reduced sample including peaks
corresponding to the cysteine containing peptides.
The peak containing the third disulfide-bonded pep-
tide contains a potential N-linked glycosylation site atTable 1
Determination of disulfide-bonded cysteines of L1R(185t)
Cys Position Tryptic
peptide
Calculated
MW of
peptide
Calculated
MW of
pair
Measured
MW of
pair
C1 34 34–44 1341.6 4439.0 4439.0
C3 57 55–84 3099.4
C2 49 45–54 1112.5 4077.0 4077.0
C5 136 128–155 2966.4
C4 116 114–125 1264.6 1866.9 1866.9
C6 158 156–161 604.3Asn117. We confirmed its presence using recently
developed software (GLYCOMATIC, Pannell). The
major component (45%, mass 2905.3) was predicted
to have two GlcNAcs, a fucose (on the first GlcNAc)
and three mannose residues. Only 11% unglycosy-
lated peptide was detected. A second glycopeptide
(mass 5115.3) was glycosylated at Asn50 and derived
from the second disulfide-bonded peptide. In this
case, only a single glycoformwas observed (disulfide +
(GlcNac)2 + Fucose + (Mannose)3) and represented
approximately 20% of the total peptide.
Monoclonal antibodies to L1R(185t) are directed at linear
or conformational epitopes
To further characterize L1R(185t) we isolated six hybrid-
oma lines that reacted against the protein by ELISA. These
were designated as VMC-2 through VMC-6 and VMC-35
(Table 2). All MAbs were isotype IgG1, except for VMC-
35, which was an IgG2b.
We electrophoresed L1R(185t) under nonreducing (Fig.
4A) or reducing conditions (Fig. 4B), prepared aWestern blot
and probed individual strips of the membrane with each
MAb. VMC-1, directed at the A33R protein of VV, was used
as a negative control. All of the MAbs against L1R(185t)
recognized the nonreduced form of L1R(185t) (Fig. 4A).
Under reducing conditions (Fig. 4B), VMC-2, VMC-3,
VMC-5 and VMC-6 reacted with three closely migrating
bands also seen in Fig. 1C. We also tested whether two
previously characterized MAbs against L1R reacted with
L1R(185t). MAbs 2D5 and 7D11 are described as IMV-
neutralizing antibodies against conformational epitopes on
L1R (Ichihashi and Oie, 1996; Ichihashi et al., 1994; Wolffe
et al., 1995). VMC-4 and 2D5 reacted only with the middle
band of reduced L1R(185t) while VMC-35 and 7D11 were
negative under these conditions. We conclude that VMC-35
and 7D11 are directed at conformational epitopes, whereas
VMC-2, VMC-3, VMC-5 and VMC-6 reacted with linear
epitopes. VMC-4 and 2D5 might be ‘‘pseudolinear’’. This
term defines antibodies that react strongly against native
protein but weakly with the denatured form. It could be that
the antibodies recognize discontinuous epitopes that were
either resistant to denaturation or that reformed during
Western blotting. Both 2D5 and 7D11 reacted with non-
reduced L1R present in extracts of VV-infected cells (Wolffe
et al., 1995). Importantly, these MAbs made to virion L1R,
i.e., authentic L1R, reacted with the baculovirus form of
L1R(185t), which is further evidence of the structural and
antigenic similarity between the two proteins. Moreover,
these data indicate that at least one neutralizing epitope of
L1R is also present within L1R(185t).
The anti-L1R MAbs neutralize IMV infectivity
Using the IMV plaque reduction assay, VMC-4 andVMC-
35 failed to neutralize IMV infectivity. In contrast, VMC-2,
Table 2
Properties of MAbs to L1R
MAb
group
MAb IMV
neutralizationa
Recognized Biosensorb
Peptidec Epitoped Bind COMP.
1 VMC-2 80 ng/ml  + 3, 5, 6
VMC-3 400 ng/ml 13, 14 118–128 + 2, 5, 6
VMC-5 2 Ag/ml 13, 14 118–128 + 2, 3, 6
VMC-6 2 Ag/ml 13, 14 118–128 + 2, 3, 5
2 VMC-4   + 35
VMC-35   + 4
3 2D5 16 ng/ml  + 7D11
7D11 16 ng/ml  + 2D5
COMP. = competes with.
a IgG concentration to obtain a 50% reduction in plaque number.
b Binding to L1R(185t) determined by surface plasmon resonance.
c Peptides (Fig. 6A) recognized by ELISA.
d Amino acid residues that form the minimal region recognized by the
MAb.
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dose-dependent manner, such that approximately 80 ng/ml
(for VMC-2), 400 ng/ml (for VMC-3) and 2 Ag/ml (for VMC-
5 and VMC-6) reduced the starting titer by 50% (Fig. 5).Fig. 4. Monoclonal antibodies to L1R(185t) recognize the purified protein
by Western blot. Purified L1R(185t) (100 ng/well) was electrophoresed
under nonreducing (A) or reducing conditions (B), transferred to nitro-
cellulose, and strips were probed with IgG of each MAb (0.5 Ag/ml) or with
serum (1:4000) from the mouse immunized with L1R(185t). VMC-1, a
MAb against VV glycoprotein A33R, was included as a negative control.
Bound IgG was detected with goat anti-mouse IgG coupled with HRP.Previous reports have documented that MAbs 2D5 and 7D11
neutralize IMV infectivity (Ichihashi et al., 1994; Wolffe et
al., 1995). We found that 7D11 and 2D5 were more potent
than our Mabs. Approximately 16 ng/ml of 2D5 or 7D11
reduced the starting titer by 50%. Thus, two MAbs did not
neutralize IMV infectivity whereas six MAbs did, suggesting
the presence of at least two antigenic sites.
Neutralizing epitopes of L1R are mapped by peptide
scanning
We used a set of 20 overlapping peptides spanning
residues 1–185 of L1R to further map the epitopes of the
eight MAbs (Fig. 6A). Each of the MAbs was tested against
the peptides using ELISA and a representative result for one
antibody, VMC-3, is depicted in Fig. 6B. We were unable to
map the epitopes for VMC-2, VMC-4, VMC-35, 2D5 or
7D11 since they did not recognize any peptide. VMC-3,
VMC-5 and VMC-6 reacted against the overlapping peptides
13 (amino acids 109–128) and 14 (amino acids 118–137),
suggesting that their epitopes are located between residues
118 and 128, which correspond to the overlapping residues of
peptides 13 and 14. Since these MAbs neutralized IMV
infectivity (Fig. 5), we propose that there is a neutralization
epitope between residues 118 and 128.
Competition: ability of anti-L1R MAbs to block binding of
each other to L1R(185t)
We performed blocking assays to enable us to analyze the
relationship between the MAbs (Aldaz-Carroll et al., 2005;
Krummenacher et al., 2000). Anti-His antibody was first
covalently coupled to the BIAcore chip and L1R(185t) was
captured by its His tag, thus presenting the protein in a nativeFig. 5. Vaccinia virus (IMV) neutralization by L1R MAbs. BSC-1 cell
monolayers were infected with IMV that were previously incubated with
MAbs VMC-2, 3, 4, 5, 6 and 35 (A) or 2D5 and 7D11 (B) for 1 h at 37 -C.
The anti-myc antibody was used as a negative control. After 18 h of
incubation at 37 -C, the cells were fixed and stained with crystal violet.
Data are expressed as the number of plaques/well. Shown is a representative
result from two experiments with duplicate measurements.
Fig. 6. Peptide scanning of L1R(185t). (A) Schematic representation of overlapping peptides spanning the ectodomain of L1R. The amino acid sequence of
L1R WR (amino acids 1–185) is indicated as a single letter code. The amino acids comprised by each peptide are represented as a black bar under the
L1R(185t) sequence and the peptide number is indicated alongside. Boxed amino acids correspond to N-glycosylation sites. The peptides analyzed by mass
spectroscopy are shaded. Peptides are 20 amino acids in length and overlap the contiguous peptide by 11 amino acids, with the exception of peptide 20. (B)
MAb VMC-3 reacts with peptides spanning residues 109–137. Each well of a streptavidin coated ELISA plate was coated with 100 pmol of purified
biotinylated peptide and incubated with purified VMC-3 (20 Ag/ml). Bound IgG was detected with anti-mouse Ig-HRP and ABTS substrate. Absorbance was
read at 405 nm. The numbers on the x-axis refer to the number of each peptide.
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to the captured L1R(185t) (Fig. 7A, step 2). All anti-L1R
MAbs bound to the captured protein (Fig. 7B). The
secondary (test) antibody was then injected as exemplified
by VMC-2 (Fig. 7C) and its binding pattern was followed.
Failure of the secondary MAb to bind to L1R(185t) suggests
that its epitope overlaps that recognized by the first MAb.
For example, VMC-2 did not bind to L1R(185t) when VMC-
2 (self), VMC-3, VMC-5 or VMC-6 was bound first. Thissuggests that these four MAbs bind to an overlapping
epitope. Binding of the second MAb indicates that it binds to
a different epitope (Aldaz-Carroll et al., 2005; Krumme-
nacher et al., 2000). For example, VMC-2 bound to
L1R(185t) in the presence of VMC-35, 2D5 or 7D11.
The complete results are presented in Fig. 8A and briefly
summarized in Table 2. Each interaction was categorized as
either a blocking interaction (black rectangle) or a non-
blocking interaction.
Fig. 7. MAb binding measured on a biosensor. (A) Example of a sensorgram
obtained from two MAbs directed against independent epitopes. First, 240
RU of L1R(185t) were captured on the chip via an immobilized anti-His
MAb (step 1), then a primary antibody was bound to the captured protein for
3 min (step 2). The test antibody was then injected and its association was
followed for another 3 min (step 3). (B) Binding of anti-L1R MAbs to
L1R(185t). MAbs were tested at 20 Ag/ml except for VMC-4 and 35 which
were tested at 500 Ag/ml. The sensorgrams are aligned at the time of injection
of eachMAb (indicated to the right). (C) Sensorgram comprising step 3 of the
binding of VMC-2 to L1R(185t) after blocking with various primary
antibodies. The binding of the test MAb to L1R(185t) in the absence of a
primary antibody is labeled ‘‘control’’ and corresponds to 100% binding (0%
blocking). Blocking of each antibody by itself (self) represents background.
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antigenic sites on L1R. Interestingly, two of these contain
epitopes recognized by neutralizing MAbs. The first anti-
genic site is defined by MAbs VMC-2, VMC-3, VMC-5 and
VMC-6, which blocked binding of each other (Figs. 7 and
8A). This is not surprising since three of these MAbs mapped
to the same set of peptides (residues 118–128) (Fig. 6B,
Table 2) and all four MAbs neutralized IMV infectivity (Fig.5A). In contrast, none of these MAbs were blocked for
binding to L1R(185t) by two other neutralizing MAbs 2D5
and 7D11 (Ichihashi and Oie, 1996; Wolffe et al., 1995).
However, these two MAbs blocked each other for binding to
L1R(185t) and define a second neutralization site. Finally, a
third antigenic site was defined by MAbs VMC-4 and VMC-
35 which recognized conformational epitopes and blocked
binding of each other to L1R(185t) (Fig. 8A). Neither MAb
was blocked by any of the other MAbs, including 2D5 and
7D11.Discussion
As a first step towards developing reagents useful in both
basic studies of VV biology and in the treatment and
prevention of disease caused by vaccinia and variola virus,
we expressed and purified soluble forms of the VV proteins
A33R (Fogg et al., 2004), L1R and B5R (Aldaz-Carroll et
al., 2005) using the baculovirus system. In this paper, we
describe the production and characterization of a soluble
recombinant form of L1R (referred to as L1R(185t)) and of
the polyclonals and MAbs raised against it. L1R was chosen
because of its well-documented importance as a target of the
protective immune response against VV. Taken together our
results show that there are at least two separate sites for
neutralizing antibodies on L1R and one of them is located
between residues 118–128.
The baculovirus-expressed L1R(185t) structurally resembles
authentic VV L1R
We first needed to check whether our recombinant
secreted protein closely resembled membrane-associated
VV L1R. We found that L1R(185t) resembles VV L1R in
several ways. L1R(185t) reacts against VIG and against
MAbs raised against authentic VV L1R. Moreover,
L1R(185t) stimulates production of VV neutralizing anti-
bodies. We found that it is disulfide bonded, as VV L1R is
expected to be (Fig. 9, orange spheres). However, L1R(185t)
differs from VV L1R because unlike the authentic protein it
is glycosylated. This difference does not seem to alter the
immunogenicity of L1R(185t) because it functions as a
vaccine (Fogg et al., 2004), it is recognized by polyclonal
antibodies and MAbs to VV L1R and it stimulates
production of neutralizing antibodies.
L1R(185t) does not inhibit neutralization by VIG
L1R is an important target of IMV neutralizing anti-
bodies (Ichihashi and Oie, 1996; Wolffe et al., 1995) and is
an important component of DNA or subunit vaccines (Fogg
et al., 2004; Hooper et al., 2000, 2003). It was surprising
that absorbing out the anti-L1R antibodies present in VIG
did not abrogate VIG’s ability to neutralize IMV (data not
shown). Thus, VIG appears to be missing specific anti-
Fig. 8. MAb blocking measured on a biosensor. (A) The table indicates the percentage of blocking when each MAb (on left) is used after the primary antibody
(at the top). The formula used to calculate the percentage of blocking is 100  (RUIg  RUself)  100 / (RUcontrol  RUself), where RUcontrol is binding in the
absence of primary MAb, RUself represents residual binding after self-blocking, RUcontrol represents 100% binding and RUself represents background
normalized to zero. Black rectangles: blocking (50–100%), white indicates limited or no blocking (0–40%). Reciprocal blocking experiments were done only
for competing pairs. ND = not determined. (B) Diagram of blocking interactions between antibodies. Blocking is represented by a black line. The number to the
top right of each antibody corresponds to the residues recognized by each antibody based on peptide mapping.
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IMV envelope. Although it remains possible that VIG
contains neutralizing antibodies to other epitopes of L1R
that are not present or are masked by glycosylation in the
recombinant protein, this seems unlikely. We theorize that
addition of anti-L1R neutralizing antibodies would improve
the efficacy of VIG.
Elucidation of two distinct neutralizing sites on L1R
In addition to making this protein for vaccine studies, we
produced six MAbs, four of which have neutralizing
activity. Interestingly, three neutralizing MAbs (VMC-3,
VMC-5 and VMC-6) mapped to residues 118–128. Thus,
these six MAbs identified at least two antigenic sites on
L1R, one of which overlaps a functional domain.
We performed competition experiments by biosensor
analysis to examine the relationships between the MAbs that
we had produced and the MAbs previously described in the
literature. The BIAcore data allowed us to place the
antibodies in three distinct groups. One group comprises
neutralizing antibodies VMC-2, VMC-3, VMC-5 and
VMC-6 (Fig. 9, yellow spheres). A second group comprises
2D5 and 7D11, both of which recognize the same epitope
although we were unable to map it. Mutants resistant to the
neutralizing effects of 2D5 were isolated by Ichihashi andOie (1996). These mutants contained a substitution of
asparagine for aspartic acid at residue 35. Since 2D5
blocked binding of 7D11 to L1R(185t), we suggest that
this amino acid is part of the epitope for both of these
MAbs. The third group comprises nonneutralizing anti-
bodies VMC-4 and VMC-35. Thus, biosensor analysis
allowed us to differentiate between neutralizing antibodies
that were undistinguishable with the other techniques.
Five MAbs (VMC-2, VMC-4, VMC-35, 2D5 and 7D11)
failed to recognize any peptide. For VMC-35 and 7D11, this
is consistent with their being directed against conformational
epitopes. The other three reacted with denatured L1R(185t)
so their inability to recognize any peptide is puzzling. It is
unlikely that carbohydrate is part of the epitope since they
recognized both glycosylated and deglycosylated forms of
L1R(185t) (data not shown). They could be directed to a
discontinuous epitope that does not require the presence of
disulfide bonds and thus is present in denatured L1R. Since
VMC-2 competed with VMC-3, VMC-5 and VMC-6, we
presume its epitope is also within amino acids 118–128.
Where are these epitopes located on the crystal structure of
L1R?
The crystal structure of amino acids 1–185 of L1R
expressed in Escherichia coli was recently solved (Su et al.,
Fig. 9. Localization of neutralizing epitopes on the crystal structure of L1R.
L1R(185t) is represented as a ribbon diagram (Su et al., 2005). The
molecule is oriented so that the carboxy-terminus (COOH) faces down-
wards towards the virion surface which would be at the bottom of the
picture. The transmembrane region (186–204) would anchor the molecule
into the virion envelope. The neutralizing epitope recognized by MAbs
VMC-3, 5 and 6 spanned residues 118–128 and is indicated by yellow
spheres. Residue 118 is hidden by residue 121 and its position has been
indicated by an arrow. The neutralizing epitope located near or at amino
acid 35 is recognized by MAb 2D5 and is indicated by a green sphere. The
cysteine pairs involved in disulfide bonds are indicated by orange spheres.
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pair of two-stranded h-sheets (Fig. 9). The disulfide bond
pattern that we elucidated in this paper is identical to that in
the crystal structure (Su et al., 2005). Interestingly, in our
protein the disulfide bonds were formed in the ER of insect
cells, whereas the disulfide bonds of the bacterial version of
L1Rwere formed during refolding of denatured protein (Su et
al., 2005). Moreover, in VV-infected cells, the disulfide
bonds form in the cytoplasm using the viral redox system.
Evidently, the disulfide bond arrangement is determined by
the intrinsic folding of L1R. We mapped the epitopes
described in this paper onto the crystal structure of L1R
(Fig. 9). The epitope recognized by MAbs VMC-3, VMC-5
and VMC-6 (residues 118–128) locates to one of the loops
connecting the a-helices to the h-sheets on the top of the
molecule as oriented in Fig. 9 (yellow spheres). Since VMC-2
competed with these MAbs its epitope is likely located in this
region as well. The epitope recognized by 2D5 (and probably
7D11) is also on the top but on a different loop (Fig. 9, green
sphere). The L1R crystal contained two molecules that make
contacts between the h-sheet regions. However, since L1R is
not a dimer in solution it has been suggested that this contact
surface is a binding site for other proteins. The neutralizing
antibodies described in this paper recognize the unstructured
loop connecting the h3-sheet to the a4-helix. It is possible
that the neutralizing MAbs mask this loop and abrogate the
interaction of the h-sheet surface of L1R with other
protein(s).Although a cellular receptor has not been identified for
VV, a viral protein that stimulates potent neutralizing
antibodies might be a viral receptor-binding protein. If
L1R bound to a cell receptor via its h-sheet surface, then
addition of soluble L1R to cells prior to infection might
block virus entry by competing with virion L1R for receptor
binding as shown for the herpesvirus glycoproteins gC (Tal-
Singer et al., 1995) and gD (Johnson et al., 1990; Nicola et
al., 1996). However, this was not the case (data not shown).
If L1R is a receptor binding protein it might bind such a
receptor with low affinity, thus making it difficult to detect
blocking. Thus, the function of L1R in virus entry is an
important subject for future study.Materials and methods
Cells and virus
BSC-1 cells were grown in DMEM supplemented with
10% fetal bovine serum and 1 penicillin–streptomycin
(Invitrogen). Vaccinia virus (WR) was propagated in BSC-1
cells. For IMV stock preparation, cells were infected at a
multiplicity of 0.05 pfu/cell and incubated at 37 -C until
cytopathic effect was complete (3–4 days). Infected cell
cultures were frozen at 80 -C and then thawed completely.
This freeze–thaw cycle was repeated 2 times to insure release
of IMV particles. The culture supernatant was cleared of
debris by centrifugation at 2000 g for 30 min at 4 -C. IMV
stocks were stored at 80 -C and consistently had titers
around 107 pfu/ml.
Construction of a recombinant baculovirus expressing
soluble VV envelope glycoprotein L1R
We expressed the extracellular portion of L1R as a
secreted, soluble form in a baculovirus expression system as
previously described for B5R (Aldaz-Carroll et al., 2005).
Briefly, we used PCR to amplify the protein coding DNA
sequence for residues 1–185 plus 6 C-terminal histidine
residues (see Fig. 1A) and then cloned the PCR product into
the baculovirus transfer vector, pVT-Bac (Sisk et al., 1994;
Tessier et al., 1991). The 6 histidine residues at its C-
terminus allowed us to purify L1R(185t) using nickel–NTA
affinity chromatography. The primers were L1R forward
primer: GGCGGATCCTGCCATGGGTGCCGCGGCAAG-
CATA; L1R reverse primer: GCCGAATTCAATGATGGTQ
GATGATGGTGCTGAACTCCTGTACCAGCAACTTQ
GTTT. The protein has been deposited at the American Type
Culture Collection.
Glycoproteins
The production and purification of B5R(275t) and
Nectin-1(346t) are described elsewhere (Aldaz-Carroll et
al., 2005; Krummenacher et al., 1998).
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R179 and R180 were generated by immunizing a
rabbit with L1R(185t) purified from the culture
supernatant of recombinant baculovirus-infected cells
as described in (Krummenacher et al., 1998). Rabbit
polyclonal antiserum R178 was raised against A33Rt
purified from the culture supernatant of recombinant
baculovirus-infected cells and rabbit polyclonal anti-
serum R176 was raised against purified herpesvirus
glycoproteins gH/gL (Cairns et al., 2005).
(ii) Hybridoma selection and IgG purification. Mice
were subcutaneously inoculated five times with 50
Ag of purified L1R(185t). The glycoprotein was
emulsified in Freunds complete adjuvant for the first
injection, whereas it was emulsified with Freunds
incomplete adjuvant for the remaining injections
given every 3 weeks. A final boost with 5 Ag of
L1R(185t) was administered intravenously in the
absence of adjuvant. Hybridoma fusion was per-
formed as previously described (Aldaz-Carroll et al.,
2005) and hybridoma secreting anti-L1R(185t) was
identified by ELISA. Hybridoma cell lines were
subcloned once from isolated colonies grown under a
soft agar overlay. Igs were purified from mouse
ascites fluids or from rabbit sera using a protein G-
based system (Hi-Trap Pro-G, Pharmacia, Inc.). IgGs
were eluted using 2.5 ml of 0.1 M glycine (pH 2.7)
and dialyzed against phosphate-buffered saline
(PBS). The anti-tetrahistidine MAb was purchased
from Qiagen Inc. The isotype of each MAb was
determined using a mouse MAb isotyping kit
(Amersham Pharmacia, USA). Hybridomas corre-
sponding to each MAb have been deposited at the
American Type Culture Collection.
(iii) VIG. The human vaccinia immunoglobulin (VIG)
used in this study was kindly supplied by Dorothy
Scott from the Food and Drug Administration.
(iv) Other MAbs. 2D5 was raised against purified VV
strain IHD-J (Ichihashi et al., 1994) and the 7D11
MAb was raised against VV [(Wolffe et al., 1995) and
(A. L. Schmaljohn, J. W. Hooper and S. A. Harrison at
the 1989 Annual Meeting of the American Society for
Virology)]. The anti-c-myc mouse MAb (9E11) used
in this study was obtained from the American Type
Culture Collection and is referenced in (Evan et al.,
1985).
SDS–PAGE
Purified recombinant glycoproteins or detergent-solubi-
lized VV-infected cell proteins were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) under nonreduced (0.1% SDS, no reducing agent,
no boiling) or reduced (samples boiled 10 min in 2.5%SDS, 350 mM h-mercaptoethanol) conditions in precast
10–20% Tris–glycine gels (Invitrogen). Following SDS–
PAGE, separated proteins were visualized by staining with
silver nitrate (Pharmacia) or were Western blotted, probed
with antibodies and visualized by ECL (Amersham).
Sedimentation velocity and equilibrium measurements of
L1R(185t)
Boundary sedimentation velocity (SV) and sedimentation
equilibrium (SE) analyses were carried out in an Optima
XLA analytical ultracentrifuge (Beckman-Coulter Instru-
ments). SV analysis was performed at 20 -C at a rotor speed
of 50,000. The centrifuge cell was filled with 300 Al of
L1R(185t) at a concentration of 0.75 mg/ml. Absorbance
scans were obtained at 230 nm. To deconvolute the
boundary velocity data into sedimenting species, we
analyzed the sedimentation coefficient distribution as
previously described using the public domain software
Sedfit (http://www.analyticalultracentrifugation.com/)
(Schuck, 2000). The results of this computational analysis
were plotted to present the distribution of sedimenting
species. Briefly, the sedimentation boundary velocity data
were subjected to maximum entropy regularization statis-
tical analysis for the most parsimonious distribution of
sedimenting species that best fit the data (Schuck, 2000). A
weight average shape factor ( f/f0) was extracted from the
boundary to convert the data to a C(M) vs. M plot, thereby
providing the molar mass of each sedimenting peak.
Sedimentation equilibrium measurements were also
taken to determine the molar mass of L1R(185t) inde-
pendently of shape factors. Cells were loaded with 130 Al
of an L1R(185t) solution at 2.82 mg/ml that had an
absorbance of 0.76 at 250 nm. Sedimentation equilibrium
absorbance data sets at radial increments of 0.001 cm with
15 repeats were obtained at two different rotor speeds,
30,000 and 32,000 rpm, at a rotor temperature of 10 -C.
The public domain software program Sedphat, developed
by Peter Schuck, was used for the analysis of the
sedimentation equilibrium data to determine molar mass
(http://www.analyticalultracentrifugation.com/).
Mass spectroscopy
20 pmol of purified L1R(185t) was digested with trypsin
(2 pmol) in 50 Al of 50 mM ammonium bicarbonate at pH
7.8. One picomole of the digest was injected into a Waters
integrated capillary liquid chromatograph QTOF Ultima
mass spectrometer system (Micromass/Waters, Beverley,
MA). The solvent gradient on a 150 mm  0.150 mm C18
column (VC-10-C18W-150, Micro-Tech Scientific, Vista
CA) was ramped from 5% acetonitrile, 95% water (both
containing 0.2% formic acid) to 90% acetonitrile, 10% water
over 3 h and mass spectra collected followed by automated
ms/ms of the highest four ions (m/z). Spectra were searched
with an in house Mascot (www.matrixscience.com) against a
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had been added. Software available at http://sx102a.niddk.
nih.gov/peptide was used to identify disulfide-bonded
peptides. The L1R(185t) glycosylation substitution was
automatically identified and characterized using GLYCO-
MATIC software recently developed at the University of
South Alabama (L. Pannell) and confirmed by the presence
of marker ions in the fragment spectra (at m/z 204.1 and
366.15).
Alkylation of L1R(185t)
100 ng of purified L1R(185t) in 50 mM Tris–HCl
(pH 8.0)–0.1% NP-40 and 1 LSB was reduced with
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP,
Sigma-Aldrich, St. Louis, MO) and alkylated with either
20 mM N-ethylmalemide (NEM, Sigma-Aldrich) or 20
mM 4-acetamido-4V-malemideylstilbene-2,2V-disulfonic
acid (AMS, Molecular Probes, Eugene, OR) by incuba-
tion at room temperature (RT) for 5 min.
Deglycosylation of L1R(185t)
15 Ag of purified L1R(185t) in 1 glycoprotein denatur-
ing buffer (New England Biolabs, Beverly, MA) was heated
for 10 min at 95 -C. Samples were then treated with 500 U of
PNGase F (NEB) in 50 mM sodium phosphate, pH 7.5, with
1%NP-40 and were incubated for 1 h at 37 -C. Samples were
subjected to SDS–PAGE and Western blotting as described
above.
IMV neutralization assay
A fixed amount of virus was combined with various
concentrations of either heat-inactivated serum or purified
IgG in DMEM containing 5% heat-inactivated FBS and
antibiotics for 1 h at 37 -C. Virus–antibody mixtures were
plated onto BSC-1 monolayers in 48-well plates (input virus
was 100 pfu/well). Plates were then incubated for 18 h at 37
-C. Infected cells were fixed with 2.5% formaldehyde for 2
h at RT, then stained for 20 min with 0.2% crystal violet and
plaques counted.
ELISA
To test whether VIG reacted with L1R(185t) wells of an
ELISA plate were first coated with 50 Al of L1R(185t) at a
concentration of 10 Ag/ml. Then serial dilutions of VIG
were added to the wells and assayed as previously described
(Aldaz-Carroll et al., 2005) (Fig. 2A).
Peptide mapping
Synthetic 20-mer peptides (peptides 1–20) were pur-
chased from Mimotopes Pty Ltd. (Melbourne, Australia)
(Tribbick, 2002). The peptides covered the entire ectodo-main of L1R and overlapped each other by 11 amino acids,
except for peptide 20 which overlapped peptide 19 by 17
amino acids (Fig. 6A). Biotin was included at the N-
terminus of each peptide during synthesis. Binding of MAbs
to peptides was determined by ELISA as previously
described (Aldaz-Carroll et al., 2005) except that the plates
were coated with 100 pmol of each peptide in PBS.
Optical biosensor analysis
Experiments were carried out on a BIAcore X optical
biosensor (BIAcore AB) at 25 -C as previously described
(Aldaz-Carroll et al., 2005; Krummenacher et al., 2000;
Willis et al., 1998).
(i) Binding properties of IgG to L1R(185t) protein. To
test the binding properties of any Ig, anti-His MAb
(Qiagen Inc.) was covalently coupled to the BIAcore
chip. Then, 250 resonance units (RU) of purified
L1R(185t) protein was captured by the antibody via
its C-terminal His-tag (Aldaz-Carroll et al., 2005).
Purified VMC IgG (20 Ag/ml, except for VMC-4 and
VMC-35 which had to be injected at 500 Ag/ml) was
then injected and the association of the complex was
followed for 3 min.
(ii) IgG blocking. In this assay, a primary antibody was
allowed to bind for 3 min to the captured L1R(185t).
The second antibody was then injected and its
association was followed for another 3 min.
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